Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05169567
Title Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | BEL


No variant requirements are available.